MIRM

Mirum Pharmaceuticals, Inc.

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$93.33

Price (1 Year)

$125.59 $65

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %23.7 / %30
Non-compliant assets / Total market cap %9.7 / %30
Non-compliant revenue / Total income %2.2 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Website

Analysis (Turkish): MIRM Hissesi Caiz mi, Helal mi? Mirum Pharmaceuticals, Inc. Katılım Analizi